Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2024

Zwierenga F, Zhang L, Melcr J, Schuuring E, van Veggel B A M H, de Langen A J, Groen H J M, Groves M R, van der Wekken A J

Abstract excerpt

INTRODUCTION: The structural effect of uncommon heterogenous in-frame deletion and/or insertion mutations within exon 20 (EGFRex20+) in relation to therapy response is poorly understood. This study aims to elucidate the structural alterations caused by EGFRex20+ mutations and correlate these changes with patient responses. MATERIAL AND METHOD: We selected EGFRex20+ mutations from advanced NSCLC patients in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Models, Molecular

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 39374568
DOI: 10.1016/j.lungcan.2024.107973

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.PMID 39374568Read ↗

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.Semantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.Semantic proximity Read ↗

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.Semantic proximity Read ↗

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Semantic proximity Read ↗

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsSemantic proximity Read ↗

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

Identification of novel inhibitors targeting EGFR L858R/T790M/C797S against NSCLC by molecular docking, MD simulation, and DFT approaches.Semantic proximity Read ↗

Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations.Semantic proximity Read ↗

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.